Integrated Cardiovascular Safety Analysis of Ritlecitinib in Patients with Alopecia Areata (AA) in the Phase 2 and Phase 3 ALLEGRO Clinical Trials, and Contextualization with a US Cohort of Patients with AA
This session was presented on March 9 2024 at the American Academy of Dermatology (AAD) Annual Meeting 2024 held in San Diego between March 8-12,